INVA Extends Strategic Reach with Nortiva Bio Launch - Long-Acting Oral Therapies Provide a New Range of Opportunities to Create Value

Research evidence excerpt

INVA Extends Strategic Reach with Nortiva Bio Launch - Long-Acting Oral Therapies Provide a New Range of Opportunities to Create Value

Investment Thesis

Innoviva is estimated to benefit from a windfall through 2030 from royalty rights for two COPD/asthma inhaled therapies

and is thoughtfully redeploying capital across a portfolio of differentiated infectious disease + critical care therapies, strategic

investments, and also directly back to shareholders. Internally marketed products exceed $180M in LTM revenue as of March 2026

at a healthy growth cadence (1Q26 revenue reflected 37% y/y growth) and focus on the hospital setting. These are areas investors

have shied away from in recent years, and INVA has recognized an opportunity to acquire cheap, master the call point at scale,

and let commercial momentum drive upside. INVA also owns majority stakes in standalone companies including Armata (ARMP,

Not Rated; first-mover phage-based antibiotics) and Syndeio (Private; novel NMDA receptor modulator for depression), a setupBIOTECHNOLOGY reminiscent of BBIO (Not Rated) prior to its successful subsidiary consolidation. A recently acquired extended release platform

for oral small molecules (weekly or better dosing) will likely also be of interest to investors and strategics. In 2026, we see strong

upside potential for INVA shares enabled through continued growth of internal commercial efforts, catalysts from INVA’s strategic

investments, and potentially accretive acquisitions (e.g., anti-fungals) where clear synergies can be realized with INVA's existing

commercial channels.EQUITY

Upcoming Catalysts Price Performance

■ Nuzolvence commercialization - 2H26 $28

■ Armata AP-SA02 Phase 3 trial initiation - 2H26 $26RESEARCH $24

$22

$20

Base Case Assumptions: $42 Price Target $18